IQVIA’s Former CFO Joins Moderna Board
The former chief financial officer of IQVIA Holdings Inc., Michael McDonnell, has been appointed to the board of directors of Moderna, Inc. The appointment, effective July 8 , 2026, was announced by Moderna’s access‑Newswire release and later reported by Finanznachrichten.de.
McDonnell’s tenure at IQVIA, a technology‑solutions and contract‑research company headquartered in Durham, North America, spanned more than a decade. During that time he led the company’s finance function while it delivered predictive and prescriptive analytics, clinical development strategies and patient‑retention services to the consumer‑health, biopharma and medical‑technology sectors. IQVIA’s market capitalization, listed on the New York Stock Exchange, stood at roughly US$34.8 billion in 2026, with a price‑to‑earnings ratio of 25.25 and a closing price of US$208.97 on July 8, 2026.
McDonnell’s expertise is expected to support Moderna’s ongoing expansion of its vaccine and therapeutic pipeline. In addition to joining the board, he will serve on the audit committee, where he can leverage his experience in capital‑allocation decisions and financial governance from his previous roles at Biogen, IntelSat and Echostar.
Moderna’s announcement underscores the company’s focus on strengthening its financial leadership as it advances its long‑term strategy. The addition of a seasoned finance executive with a deep background in life‑sciences technology firms is intended to enhance the board’s oversight of Moderna’s growth and transformation initiatives.
